Fr-221647

Fr-221647

SCHEMBL7659103

NC(=O)c1cn(C(CO)CCc2ccccc2)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ADA P00813 18/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27547750 0.89 ADA (0.80) ADA
SCHEMBL7457279 0.88 ADA (0.78) ADA
SCHEMBL7668630 0.88 ADA (0.78) ADA
SCHEMBL7668636 0.88 ADA (0.78) ADA
SCHEMBL6173086 0.88 ADA (0.78) ADA
SCHEMBL7668671 0.87 ADA (0.77) ADA
SCHEMBL7664981 0.87 ADA (0.77) ADA
SCHEMBL7670504 0.86 ADA (0.75) ADA
SCHEMBL7663098 0.85 ADA (0.74) ADA
SCHEMBL27547811 0.85 ADA (0.74) ADA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1291979-C Imidazole compounds and their use as adenosine deaminase inhibitors JUJISAWA PHARAMCEUTICAL CO LTD (JP) 2006-12-27 CN claimed
US-6359145-B1 ADENOSINE DEAMINASE INHIBITOR; ANTIINFLAMMATORY AGENTS; IMMUNOSUPPRESSANT FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-19 US claimed
CN-1319095-A Imidazole compounds and their use as adenosine deaminase inhibitors JUJISAWA PHARAMCEUTICAL CO LTD (JP) 2001-10-24 CN claimed
EP-4735431-A2 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2026-05-06 EP disclosed
EP-4735446-A1 SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 GILEAD SCIENCES, INC. (US) 2026-05-06 EP disclosed
US-20260035374-A1 PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES GILEAD SCIENCES INC (US) 2026-02-05 US disclosed
EP-4674484-A2 THIENOPYRROLE COMPOUNDS Gilead Sciences, Inc. (US) 2026-01-07 EP disclosed
US-12415808-B2 Pyrrolo[1,2-b]pyridazine derivatives GILEAD SCIENCES, INC. (US) 2025-09-16 US disclosed
EP-4291562-B1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES INC (US) 2025-09-10 EP disclosed
US-12240862-B2 Inhibitors of peptidylarginine deiminases GILEAD SCIENCES, INC. (US) 2025-03-04 US disclosed
US-20250049780-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2025-02-13 US disclosed
WO-2022140428-A2 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2022-06-30 WO disclosed
WO-2022140326-A1 SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-06-30 WO disclosed
WO-2022140325-A1 6-SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-06-30 WO disclosed
US-20220098187-A1 THIADIAZOLE IRAK4 INHIBITORS GILEAD SCIENCES, INC. 2022-03-31 US disclosed
CN-1291979-C Imidazole compounds and their use as adenosine deaminase inhibitors JUJISAWA PHARAMCEUTICAL CO LTD (JP) 2006-12-27 CN disclosed
US-6359145-B1 ADENOSINE DEAMINASE INHIBITOR; ANTIINFLAMMATORY AGENTS; IMMUNOSUPPRESSANT FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-19 US disclosed
CN-1319095-A Imidazole compounds and their use as adenosine deaminase inhibitors JUJISAWA PHARAMCEUTICAL CO LTD (JP) 2001-10-24 CN disclosed
EP-1098885-A1 IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-05-16 EP disclosed
WO-2000005217-A1 IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035374-A1 PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES IRAK4, IRAK1, IRAK2 ADA 3827/4885
US-20220098187-A1 THIADIAZOLE IRAK4 INHIBITORS IRAK4, IRAK3, IRAK1 ADA 1848/4885
US-20250049780-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 ADA 1185/4885
US-12415808-B2 Pyrrolo[1,2-b]pyridazine derivatives CYP11B2, CYP11B1, DHPS ADA 2376/4885
US-12240862-B2 Inhibitors of peptidylarginine deiminases PADI4, PADI2, PADI1 ADA 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.